Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models

• Published in: Cancer chemotherapy and pharmacology 2010-05, Vol.66 (1), p.43-52
• Main Authors: Gabizon, Alberto, Tzemach, Dina, Gorin, Jenny, Mak, Lidia, Amitay, Yasmine, Shmeeda, Hilary, Zalipsky, Samuel
• Format: Article
• Language: English
• Subjects: Animals; Antibiotics, Antineoplastic - administration & dosage; Antibiotics, Antineoplastic - chemistry; Antibiotics, Antineoplastic - pharmacokinetics; Antineoplastic agents; Biological and medical sciences; Cancer Research; Carrier Proteins - metabolism; Cell Line, Transformed; Cell Line, Tumor; Cell Survival - drug effects; Doxorubicin - administration & dosage; Doxorubicin - analogs & derivatives; Doxorubicin - chemistry; Doxorubicin - pharmacokinetics; Drug Delivery Systems - methods; Female; Folate Receptors, GPI-Anchored; Folic Acid - administration & dosage; Folic Acid - chemistry; Humans; Injections, Intraperitoneal; Injections, Intravenous; Liposomes - administration & dosage; Liposomes - chemical synthesis; Liposomes - pharmacokinetics; Medical sciences; Medicine; Medicine & Public Health; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms - drug therapy; Neoplasms - metabolism; Oncology; Original Article; Pharmacology. Drug treatments; Pharmacology/Toxicology; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - chemistry; Polyethylene Glycols - pharmacokinetics; Receptors, Cell Surface - metabolism; Xenograft Model Antitumor Assays
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-009-1132-4

Purpose The folate receptor (FR) is overexpressed in a broad spectrum of malignant tumors and represents an attractive target for selective delivery of anti-cancer agents to FR-expressing tumors. Targeting liposomes to the FR has been proposed as a way to enhance the effects of liposome-based chemotherapy. Methods Folate-polyethylene glycol-distearoyl-phosphatidyl-ethanolamine conjugate was inserted into pegylated liposomal doxorubicin (PLD). The therapeutic activity of folate-targeted (FT-PLD) and non-targeted (PLD) pegylated liposomal doxorubicin was tested in two human tumor models (KB, KB-V) and in one mouse ascitic tumor model (FR-expressing J6456) by the i.v. systemic route in all models, and by the i.p. intracavitary route in the ascitic tumor model only. Results Consistent with previous studies, PLD was clearly superior to free doxorubicin in all tumor models. When targeted and non-targeted liposome formulations were compared, FT-PLD was more effective than PLD in the KB and KB-V xenograft models, and in the J6456 intra-cavitary therapy model. The therapeutic effect was dose-dependent in the KB model and schedule-dependent in the J6456 intra-cavitary therapy model. In some experiments, toxic deaths aggravated by folate-depleted diet were a major confounding factor. In a non-FR expressing J6456 model, FT-PLD was as active as PLD indicating that its activity is not limited to FR-expressing tumors. Conclusion Folate-targeting confers a significant albeit modest therapeutic improvement to PLD in FR-expressing tumor models, which appears particularly valuable in intracavitary therapy. The potential clinical added value of this approach has yet to be determined.